Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioNTech SE ( (BNTX) ) has provided an announcement.
On August 27, 2025, BioNTech SE and Pfizer Inc. announced that the U.S. Food and Drug Administration approved their LP.8.1-adapted monovalent COVID-19 vaccine, COMIRNATY® LP.8.1, for adults aged 65 and older, and individuals aged 5 through 64 with underlying conditions at high risk for severe COVID-19 outcomes. This approval is based on extensive clinical and real-world data demonstrating the vaccine’s safety and efficacy. The vaccine targets the SARS-CoV-2 sublineage LP.8.1, aligning with FDA guidance to address circulating strains. Shipping of the vaccine will commence immediately to ensure availability in pharmacies, hospitals, and clinics across the U.S., reinforcing BioNTech’s and Pfizer’s positions in the vaccine market and their commitment to addressing public health needs.
The most recent analyst rating on (BNTX) stock is a Hold with a $120.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
Spark’s Take on BNTX Stock
According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.
BioNTech’s overall stock score reflects significant financial and technical challenges. While strategic collaborations and revenue growth are positives, the company’s profitability issues and bearish technical indicators weigh heavily on the score. The negative valuation metrics further contribute to a cautious outlook.
To see Spark’s full report on BNTX stock, click here.
More about BioNTech SE
BioNTech SE is a biotechnology company that specializes in developing and manufacturing immunotherapies for cancer and infectious diseases. The company is known for its mRNA-based vaccines, including the widely used COVID-19 vaccine developed in collaboration with Pfizer.
Average Trading Volume: 844,112
Technical Sentiment Signal: Sell
Current Market Cap: $25.19B
Find detailed analytics on BNTX stock on TipRanks’ Stock Analysis page.